DNTH.US Dianthus Therapeutics Inc.

Healthcare Biotechnology USA Stocks
91.81 USD
Close of Nov 13, 2026
35.84 117.88
Market cap
USD 5.17B
P/E
-
P/B
4.20x
ROE
-14.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DNTH.US undervalued?

Graham number

The Graham number of Dianthus Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dianthus Therapeutics Inc. fundamental analysis

No fundamental analysis for Dianthus Therapeutics Inc. yet.

Dianthus Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production…

Full company profile